ENDO INTERNATIONAL PLC

(ENDP)
  Report
Real-time Estimate Cboe BZX  -  05/16 03:08:21 pm EDT
1.185 USD   -1.25%
05/09BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market Perform Rating
MT
05/09Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight Rating
MT
05/06Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $1 From $3
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo Announces Publication of New AVEED« (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

01/13/2022 | 07:30am EDT

Endo International plc announced the publication of data from a population pharmacokinetic (PK) modeling and simulation study, evaluating potential dosing flexibility of AVEED® (testosterone undecanoate) in hypogonadal males. The objective of this population PK analysis was to assess the potential impact of a more frequent dose regimen of testosterone undecanoate (8 weeks vs. 10 weeks) on exposure parameters of clinical interest. The current FDA-approved recommended dose of AVEED® is 3 mL (750 mg) injected intermuscularly, followed by 3 mL (750 mg) injected after 4 weeks, then 3 mL (750 mg) injected every 10 weeks thereafter. The findings from this PK model and simulation were published in The Journal of Clinical Pharmacology. See online version of the article. AVEED® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone "releasing hormone (LHRH) deficiency or pituitary "hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. AVEED® should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism and anaphylaxis.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ENDO INTERNATIONAL PLC 0.00% 1.1828 Delayed Quote.-68.09%
ON SEMICONDUCTOR CORPORATION -1.25% 55.65 Delayed Quote.-17.29%
All news about ENDO INTERNATIONAL PLC
05/09BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market ..
MT
05/09Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight R..
MT
05/06Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $..
MT
05/06Top Midday Decliners
MT
05/06Endo International Posts Lower Q1 Adjusted Earnings, Revenue; Issues Q2 Guidance; Share..
MT
05/06ENDO INTERNATIONAL PLC Management's Discussion and Analysis of Financial Condition and..
AQ
05/06Wall Street Set for Downbeat Session; US Jobs Report Shows Strong Gain
MT
05/06Top Premarket Decliners
MT
05/06TRANSCRIPT : Endo International plc, Q1 2022 Earnings Call, May 06, 2022
CI
05/05ENDO : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2022 2 321 M - -
Net income 2022 -269 M - -
Net Debt 2022 7 378 M - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 282 M 282 M -
EV / Sales 2022 3,30x
EV / Sales 2023 3,61x
Nbr of Employees 3 103
Free-Float 99,1%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 5
Last Close Price 1,20 $
Average target price 1,33 $
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
James Patrick Tursi Executive VP-Global Research & Development